tucatinib,trastuzumab
seagen,roche
['solid tumor', 'urothelial', 'sclc', 'sgntuc-019', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib', 'nsclc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'breast', 'basket study']
a phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with her2 alterations: #urothelialcancer cohort (sgntuc-019). presented by evan yu, md . #gu23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology